Aydin et al.
(t, J ) 7.6 Hz, 2H), 7.15-7.34 (m, 9H), 6.83 (d, J ) 8.0 Hz, 2H),
2.62 (s, 6H), 2.50 (s, 6H). 13C NMR (100.5 MHz, CDCl3) δ 156.7,
156.5, 145.0, 144.97, 143.6, 133.1, 132.7, 132.3, 132.0, 131.7,
129.91, 129.85, 127.4, 127.22, 127.16, 126.9, 126.3, 126.2, 126.1,
125.6, 125.4, 125.1, 122.5, 122.4, 108.2, 108.1, 15.07, 14.99. 31P
NMR (121.4 MHz, CDCl3) δ 150.2. MALDI-TOF MS for 1a:
(M+ - I-) 1028.043, C50H35O6P2PdS4. Optical rotation data for
1a: [R]D ) -544° (c ) 0.67, CHCl3). Spectral data for 1b: 1H
NMR (400 MHz, CDCl3) δ 7.89 (d, J ) 8.0 Hz, 2H), 7.79 (d, J )
8.0 Hz, 2H), 7.76 (s, 2H), 7.60 (s, 2H), 7.48 (t, J ) 7.6 Hz, 2H),
7.42 (t, J ) 7.6 Hz, 2H), 7.17-7.34 (m, 9H), 6.82 (d, J ) 8.0 Hz,
2H), 2.63 (s, 6H), 2.50 (s, 6H). 13C NMR (100.5 MHz, CDCl3) δ
156.6, 156.5, 156.4, 145.0, 143.6, 133.1, 132.7, 132.3, 132.0, 131.7,
129.91, 129.85, 127.4, 127.22, 127.16, 126.9, 126.3, 126.2, 126.1,
125.6, 125.4, 125.1, 122.5, 122.4, 108.2, 108.1, 108.0, 15.07, 14.99.
31P NMR (161.9 MHz, CDCl3) δ 150.2. MALDI-TOF MS for 1b:
(M+ - I-) 1028.112, C50H35O6P2PdS4. Optical rotation data for
1b: [R]D ) +542° (c ) 0.59, CHCl3).
mmol) or potassium trifluoroallylborate 3 (0.0296 g, 0.20 mmol)
was added to a mixture of sulfonimine 4a-e (0.10 mmol) and the
corresponding catalyst 1a-f (0.005 mmol, 5.0 mol %) in 1.0 mL
of solvent. The reaction mixture was then stirred for the allotted
times and temperatures (Table 1). The crude product was purified
by silica gel chromatography (pentane/ethyl acetate 9:2) affording
the corresponding homoallylic amine 5a-g. The enantiomeric
excess was determined by chiral-phase HPLC (Daicel Chiracel
OD-H and AD-H columns).
N1-(1-Phenyl-3-butenyl)-1-benzenesulfonamide (5a). 1H NMR
(400 MHz, CDCl3) δ 7.66 (d, J ) 7.7 Hz, 2H), 7.45 (t, J ) 7.7
Hz, 1H), 7.33 (t, J ) 7.7 Hz, 2H), 7.15 (m, 3H), 7.06 (m, 2H) 5.52
(m, 1H), 5.06 (br d, J ) 12.9 Hz, 3H), 4.42 (q, J ) 6.9 Hz, 1H),
2.47 (br s, 2H). 13C NMR (100.5 MHz, CDCl3) δ 140.4, 140.1,
133.0, 132.3, 128.7, 128.4, 127.4, 127.1, 126.5, 119.3, 57.2, 41.9.
HRMS m/z 310.0875 (calcd [M + Na]+ for C16H17NaNO2S
310.0872). [R]D ) +47° (c ) 0.27, CHCl3) corresponding to 73%
ee. The enantiomeric excess of 5a was determined by chiral-phase
HPLC (Daicel Chiracel OD-H, hexane/iPrOH 95:5, flow rate 1.0
mL/min): major enantiomer tr ) 13.1 min, minor enantiomer tr )
18.0 min.
N1-(1-Phenyl-3-butenyl)-1-benzenesulfonamide (5b). The above
general procedure was employed except that 2 was added slowly
(in 24 h) to the reaction mixture, when 1f was employed as catalyst
(Table 1, entries 13 and 14). The NMR and HRMS data are identical
to those for 5a. [R]D ) -52° (c ) 0.21, CHCl3) corresponding to
83% ee. The enantiomeric excess of 5b was determined by chiral-
phase HPLC (Daicel Chiracel OD-H, hexane/iPrOH 95:5, flow rate
1.0 mL/min): minor enantiomer tr ) 13.1 min, major enantiomer
tr ) 18.0 min.
Synthesis of Complex 1c. This complex was prepared from 6c
1
by the above general procedure, yielding 63 mg (27%) of 1c. H
NMR (300 MHz, CDCl3) δ 7.84-7.93 (m, 4H), 7.79 (d, J ) 8.0
Hz, 2H), 7.72 (s, 2H), 7.37-7.54 (m, 4H), 7.14-7.36 (m, 9H),
6.81 (d, J ) 8.0 Hz, 2H), 2.93-3.24 (m, 8H), 1.42 (t, J ) 7.3 Hz,
6H), 1.34 (t, J ) 7.3 Hz, 6H). 13C NMR (75.4 MHz, CDCl3) δ
156.9 156.7, 145.7, 144.0, 132.3, 132.2, 131.9, 130.5, 130.3, 130.0,
129.9, 128.1, 127.8, 127.6, 127.3, 127.0, 126.3, 126.1, 125.9, 125.5,
122.9, 122.8, 108.0, 26.7, 26.5, 13.9, 13.5. 31P NMR (121.4 MHz,
CDCl3) δ 150.6. MALDI-TOF MS for 1c: (M+ - I-) 1084.059,
C54H43O6P2PdS4. Optical rotation data for 1c: [R]D ) -517° (c )
0.87, CHCl3).
Synthesis of Complex 1d. This complex was prepared from 6d
by the above general procedure, yielding 0.167 g (62%) of 1d. 1H
NMR (400 MHz, CDCl3) δ 7.69 (d, J ) 8.3 Hz, 4H), 7.58-7.64
(m, 8H), 7.52 (br d, J ) 7.0 Hz, 4H), 7.29-7.45 (m, 15H), 7.15-
7.25 (m, 10H), 6.76 (d, J ) 8.0 Hz, 2H). 13C NMR (100.5 MHz,
CDCl3) δ 156.6, 156.4, 156.3, 145.3, 144.3, 133.8, 133.6, 132.6,
132.22, 132.16, 131.9, 131.5, 131.1, 131.0, 130.7, 130.6, 130.1,
130.0, 129.6, 129.2, 128.4, 128.1, 127.9, 127.6, 127.2, 127.1, 126.2,
126.1, 123.1, 122.9, 108.2, 108.1, 108.0. 31P NMR (161.9 MHz,
CDCl3) δ 151.0. MALDI-TOF MS for 1d: (M+ - I-) 1276.042,
C70H43O6P2PdS4. Optical rotation data for 1d: [R]D ) -342° (c )
1.08, CHCl3).
N1-[1-(1,3-Benzodioxol-5-yl)-3-butenyl]-4-methyl-1-benzene-
sulfonamide (5c). 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J ) 8.1
Hz, 2H), 7.16 (d, J ) 8.1 Hz, 2H), 6.56 (m, 3H), 5.87 (dd, J ) 1.3
and 9.5 Hz, 2H), 5.51 (m, 1H) 5.03 (m, 3H), 4.27 (q, J ) 6.7 Hz,
1H), 2.43 (m, 5H). 13C NMR (100.5 MHz, CDCl3) δ 147.6, 146.8,
143.0, 137.5, 134.3, 133.1, 129.2, 127.2, 120.2, 119.2, 107.9, 106.9,
101.0, 57.0, 41.8, 21.4. HRMS m/z 386.0928 (calcd [M + Na]+
for C18H19NaNO4S 368.0927). [R]D ) +29° (c ) 0.16, CHCl3)
corresponding to 48% ee. The enantiomeric excess of 5c was
determined by chiral-phase HPLC (Daicel Chiracel OD-H, hexane/
iPrOH 95:5, flow rate 1.0 mL/min): major enantiomer tr ) 24.1
min, minor enantiomer tr ) 31.7 min.
N1-1-[(E)-2-Phenyl-1-ethenyl]-3-butenyl-4-methyl-1-benzene-
sulfonamide (5d). 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J ) 8.0
Hz, 2H), 7.24 (m, 5H), 7.14 (d, J ) 8.0 Hz, 2H), 6.3 (d, J ) 15.9
Hz, 1H), 5.81 (dd, J ) 7.0 Hz, 1H), 5.65 (m, 1H), 5.1 (m, 2H),
4.62 (d, J ) 7.2 Hz, 1H), 4.04 (m, 1H), 2.33 (br s, 5 H). 13C NMR
(100.5 MHz, CDCl3) δ 143.3, 138.0, 136.2, 132.7, 131.6, 129.5,
128.4, 128.3, 127.7, 127.3, 126.4, 119.5, 55.1, 40.2, 21.4. HRMS
m/z 350.1181 (calcd [M + Na]+ for C19H21NaNO2S 350.1185). [R]D
) -35° (c ) 0.26, CHCl3) corresponding to 59% ee. The
enantiomeric excess of 5d was determined by chiral-phase HPLC
(Daicel Chiracel OD-H, hexane/iPrOH 95:5, flow rate 1.0 mL/
min): major enantiomer tr ) 23.9 min, minor enantiomer tr ) 26.5
min.
N1-[1-(3-Nitrophenyl)-3-butenyl]-4-methyl-1-benzenesulfona-
mide (5e). 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J ) 7.9 Hz, 1H),
7.84 (s, 1H), 7.52 (d, J ) 7.8 Hz, 3H), 7.39 (t, J ) 7.9 Hz, 1H),
7.13 (d, J ) 7.1 Hz, 2H), 5.5 (m, 1H), 5.1 (m, 3H), 4.49 (q, J )
6.3 Hz, 1H), 2.44 (t, J ) 7 Hz, 2H), 2.35 (s, 3H). 13C NMR (100.5
MHz, CDCl3) δ 148.1, 143.7, 142.6, 137.0, 133.0, 131.9, 129.5,
129.3, 127.1, 122.4, 121.7, 120.6, 56.3, 41.7, 21.4. HRMS m/z
369.0871 (calcd [M + Na]+ for C17H18NaN2O4S 369.0879). [R]D
) -67° (c ) 1.15, CHCl3) corresponding to 66% ee. The enantio-
meric excess of 5e was determined by chiral-phase HPLC (Daicel
Chiracel AD-H, hexane/iPrOH 95:5, flow rate 1.2 mL/min): minor
enantiomer tr ) 28.7 min, major enantiomer tr ) 33.5 min.
N1-[1-(3-Nitrophenyl)-3-butenyl]-4-methyl-1-benzenesulfona-
mide (5f). The above general procedure was employed except that
Synthesis of Complexes 1e and 1f. These complexes were
prepared from 6e or 6f by the above general procedure except that
the first (6e,f f 7e,f) and the second (7e,f f 8e,f) steps were run
for 24 and 48 h, respectively, at 35 °C, yielding 60% 1e or 1f.
These complexes were purified by using CH2Cl2/pentane (1:1) as
eluent. Spectral data for 1e: 1H NMR (300 MHz, CDCl3) δ 8.82
(m, 4H), 8.69 (m, 4H), 8.44 (m, 2H), 8.26 (d, J ) 8.2 Hz, 2H),
7.82 (t, J ) 7.5 Hz, 2H), 7.65 (m, 10H), 7.34 (m, 9H), 6.66 (d, J
) 7.9 Hz, 2H). 13C NMR (75.4 MHz, CDCl3) δ 156.4, 156.3, 156.1,
144.6, 144.3, 131.9, 131.7, 130.65, 130.5, 129.3, 129.1, 128.3,
127.5, 127.4, 126.8, 126.7, 126.5, 126.2, 124.1, 123.1, 123.04,
123.0, 122.7, 122.5, 120.8, 119.95, 108.4, 108.3, 108.2. 31P NMR
(121.4 MHz, CDCl3) δ 153.3. MALDI-TOF MS for 1e: (M+
-
I-) 1043.194, C62H35O6P2Pd. Optical rotation data for 1e: [R]D )
+586° (c ) 0.91, CHCl3). Spectral data for 1f: 1H NMR (400
MHz, CDCl3) δ 8.82 (m, 4H), 8.69 (m, 4H), 8.44 (m, 2H), 8.26
(d, J ) 8.2 Hz, 2H), 7.82 (t, J ) 7.5 Hz, 2H), 7.66 (m, 8H), 7.58
(t, J ) 7.5 Hz, 2H), 7.45 (d, J ) 8.2 Hz, 2H), 7.41 (d, J ) 8.2 Hz,
2H), 7.28 (m, 5H), 6.66 (d, J ) 7.9 Hz, 2H). 13C NMR (100.5
MHz, CDCl3) δ 156.4, 156.3, 156.2, 144.6, 144.3, 131.9, 131.7,
130.7, 130.5, 129.3, 129.1, 128.3, 127.5, 127.4, 126.8, 126.7, 126.5,
126.2, 124.1, 123.1, 123.04, 123.0, 122.7, 122.5, 120.8, 119.9,
108.4, 108.3, 108.2. 31P NMR (161.9 MHz, CDCl3) δ 153.4.
MALDI-TOF MS for 1f: (M+ - I-) 1043.333, C62H35O6P2Pd.
Optical rotation data for 1f: [R]D ) -588° (c ) 0.55, CHCl3).
General Procedure for Palladium Pincer Complex-Catalyzed
Allylation of Imines 4a-e. Tributylallylstannane 2 (0.062 mL, 0.20
4696 J. Org. Chem., Vol. 72, No. 13, 2007